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ABSTRACT 
 
Acela A. Martínez Luna: Osteogenic activity associated with dental implant placement in 
patients with type 2 diabetes mellitus as compared to healthy individuals.  
(Under the direction of Steven Offenbacher) 
Objectives: To identify differentially expressed genes and molecular pathways that 
modulate osseous healing around implants in patients with diabetes as compared to healthy 
individuals. Materials and Methods: 4 healthy subjects and 6 patients with type 2 diabetes that 
required implant placement were enrolled in the study. For each patient, two titanium test 
cylinders were placed in the mandible, and were removed at two and four weeks using a trephine 
drill. Bone biopsies were processed for RNA extraction. Whole transcriptome analysis was 
performed using Affymetrix (Affymatrix Inc, Santa Clara, CA) and confirmed with quantitative 
PCR using an array for human osteogenesis genes. Results: Analysis revealed that patients with 
T2DM presented downregulation of SPP1, BMPR1B, IGF-1; and an increased expression of 
SOST, and osteogenesis genes at 4 weeks as compared to healthy individuals.  Conclusion: 
patients with T2DM presented with delayed osseous healing since we observed decreased 
expression of important genes involved in osseous healing, and increased expression of early 
transcription factors and important osteogenesis genes at later stages as compared to healthy 
individuals.  
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CHAPTER 1: REVIEW OF DENTAL IMPLANTS IN PATIENTS WITH DIABETES 
MELLITUS 
 
Introduction 
 
Diabetes mellitus (DM) is a chronic metabolic disorder characterized by hyperglycemia 
due to impaired insulin secretion, insufficient insulin action or both.1   Type 1 Diabetes Mellitus 
(T1DM) is characterized by an absolute insulin deficiency and accounts for only 5 to 10% of all 
patients with DM. Type 2 diabetes mellitus (T2DM) is characterized by impaired insulin 
function and accounts for 90% to 95% of all patients with DM.2  Patients with DM represent a 
significant portion of the population. In 2012, 29.1 million Americans, or 9.3% of the population 
had diabetes. Of the 29.1 million, 21.0 million were diagnosed, and 8.1 million were 
undiagnosed.3   
The number of individuals with DM will continue to increase as the population ages.  
In this aging population, in which both tooth loss and DM coexist, the need for implant therapy 
may be the greatest, and they can benefit from an implant-based oral rehabilitation to enhance 
their well being.4  
The use of dental implants in patients with DM is a debatable issue due to the adverse 
effects of hyperglycemia on osseointegration.5 Although dental implant therapy is an effective 
treatment modality, the predictability relies on the osseointegration formed during the healing 
period,6  and the critical dependence on bone metabolism for implant survival may be heightened 
in patients with DM.4  
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Several studies have demonstrated that successful osseointegration of dental implants 
could be achieved in diabetic patients with well-controlled glycemic level.7-18 However, other 
studies, most of which are experimental, have reported that DM could negatively affect the 
osseointegration of dental implants.19-25 
The effect of diabetes mellitus on wound healing  
The underlying pathophysiology that may be responsible for impaired wound healing and 
osseointegration has been related to several mechanisms. A consequence of sustained 
hyperglycemia is the alteration of circulating and immobilized proteins. When proteins such as 
collagen, or lipids, are exposed to aldose sugars, they undergo nonenzymatic glycation26 and 
oxidation.27 Initially, reversible alterations of the proteins exposed to sugars are seen, and 
eventually, complex molecular rearrangements may occur.28 These proteins become altered by 
irreversible glycation, resulting in the formation of advanced glycation end products (AGEs),28,29 
and their formation and accumulation is related to the glucose concentration and time.26, 27 AGEs 
cause qualitative and quantitative changes in extracellular matrix (ECM) components such as 
collagen, laminin and vitronectin.30  These changes affect cell adhesion, growth, and matrix 
accumulation.6 AGEs present in collagen increase collagen cross-linking and result in the 
formation of highly stable collagen macromolecules, which accumulate in tissues due to their 
resistance to normal enzymatic degradation and tissue turnover.31 Studies have shown that AGEs 
affect the normal network-like assembly during matrix formation due to inhibition of the lateral 
association of collagens.6,26,32,33 Increased levels of AGEs in bone collagen may affect cellular, 
structural and functional characteristics leading to alterations in bone metabolism.34-36  Bone 
formation is decreased with elevated levels of AGE collagen,37 and this has been linked to an 
alteration on ECM production and osteoblastic differentiation.38, 39 The possible role of AGE 
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collagen in bone resorption is not clear, some studies have shown an increase in osteoclasts and 
resorptive markers.29,40-42 In contrast, other studies have reported that decreased bone resorption 
may occur.43-45 Therefore, the role of AGEs on bone resorption are likely most relevant to the 
inflammatory response.29 Other collagen abnormalities that predispose patients with DM to 
impaired wound healing have been recognized, including a decrease in collagen synthesis and 
solubility in gingiva and bone, and an increment in the urinary excretion of hyrdoxyproline, 
which is a marker of collagen degradation.28   
AGEs interact with receptors for AGEs (RAGEs) present on endothelial cells, smooth 
muscle cells, neurons, and monocytes/macrophages.46 The wound healing capacity of patients 
with DM is impaired since endothelial cell basement membranes build up AGE modified 
collagen causing an increased thickness in the microvasculature leading to an altered normal 
homeostatic transport across the membrane,47 impaired migration of leukocytes, decreased 
oxygen diffusion, and elimination of metabolic waste.28,48 AGEs interact with RAGEs present on 
monocytes increasing cellular oxidant stress and activating the transcription factor nuclear factor 
kappa-B (NF-kB), which alters the monocyte/macrophage phenotype resulting in an increase of 
proinflammatory cytokines including interleukin-1 beta (IL-1β), tumor necrosis factor-alpha 
(TNF-α)46,47 and interleukin-6 (IL-6).49 Also, this interaction stimulates the production of 
enzymes (i.e matrix metalloproteinases or MMPs) and adhesion molecules.50  An overproduction 
of these products could help mediate and/or be in addition to alterations in collagen metabolism, 
and thus amplify the inflammatory response, delaying wound healing and inducing bone 
resorption and connective tissue damage.51 Hyperglycemia is also associated with an impaired 
metabolism including: defective migration of polymorphonuclear leukocytes, impaired 
phagocytosis, and exaggerated inflammatory response to microbial products.52 
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The effect of diabetes on osseous healing has been extensively studied and several 
molecular mechanisms implicated in impaired bone healing have been postulated. In vitro 
studies have demonstrated that exposure of osteoblastic cells to hyperglycemic conditions cause 
a decrease in cell-growth rate,53 decrease in differentiation potential, inhibition in calcium uptake 
and formation of irregular bone nodules.54 Furthermore, altered gene expression has been 
observed, it has been reported that MMP13, osteocalcin (OCN), collagen-I and c-Jun mRNA 
levels were decreased followed prolonged exposure of osteoblastic cells to hyperglycemia.55,56 
Plausible pathogenic mechanisms responsible for this osteoblastic response to increased glucose 
concentrations include non-enzymatic protein glycation, modulation of the redox state, activation 
of the protein kinase C pathway and increased activity of the polyol-pathway.56 Models of 
experimentally induced diabetes have shown decreased cellularity and impaired osteoid matrix 
production during the early phases of osseous healing possibly due to a deficit in the recruitment 
of mesenchymal stem cells (MSCs) in the osteoblastic lineage, impaired differentiation and 
proliferation of cells of the osteoblastic lineage, and suppressed osteoblastic activity.56,57 
Decreased expression of transcription factors necessary for the acquisition of the osteoblastic 
phenotype was observed in the early phase of intramembranous bone healing in the marrow 
ablation model, suggesting a possible mechanism of impaired commitment of MSCs in the 
osteoblastic lineage.58 In regard to a possible mechanism of reduced proliferation of osteoblastic 
cells, a gene expression profiling study demonstrated that uncontrolled diabetes showed 
downregulation of pathways involved in cell division, energy production and osteogenesis during 
the proliferative phase of intramembranous bone healing.59 A plausible mechanism responsible 
for the reduction in cell proliferation is that diabetes may decrease the levels of growth factors 
involved in early osteogenesis by altering the normal progression of the inflammatory phase and 
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osseous formation.60,61 Several studies conducted on diabetic animal models to assess fracture 
healing have reported decreased expression of important mitogenic factors for MSCs during 
osseous healing such as fibroblast growth factor (FGF)62 and platelet derived growth factor 
(PDGF),60 and other important growth factors for osteogenesis including transforming growth 
factor βI (TGF-β1), insulin-like growth factor-1 (IGF-1) and vascular endothelial growth factor 
(VEGF) at fracture sites.60,61 Another possible explanation of the impaired osseous healing 
observed in diabetes due to suppressed osteoblastic activity is supported by studies that have 
reported a decrease in collagen content63,64   and a reduced mRNA expression of OCN,58 which is 
an important noncollagenous bone matrix protein secreted by osteoblasts. With regard to 
intramembranous ossification, which is the ossification process seen in the mandible, histological 
and histomorphometric studies have demonstrated that experimental diabetes impaired the 
intramembranous bone potential mainly after the first and during the second week of osseous 
healing.59 Furthermore, experimental diabetes models have demonstrated an alteration of mineral 
homeostasis and a decrease in osteoid production and bone formation.65-67 Bone turnover is 
reduced as measured by the percentage of osteoclasts, osteoblats, osteoid surface present, failure 
to uptake tetracycline labeling and decreases in osteocalcin synthesis.68  Histomorphometry 
studies have reported diminished bone mineral apposition, osteoid formation and matrix 
volume.65,69 These studies have also demonstrated impaired microarchitectural bone quality due 
to poor trabecular connectivity, increased porosity, and lower bone spicule/marrow space 
ratio.70,71 
Impact of diabetes mellitus on dental implant therapy 
Experimental studies have demonstrated an impaired osseous healing response to implant 
placement in diabetic animals as compared to non-diabetic controls, both quantitatively and 
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qualitatively.72  In regard to histologic analysis of wound healing response, one of the initial 
studies conducted by Iyama et al. demonstrated impaired new bone formation following 
implantation of hydroaxypatite-coated implants in rat tibiae.73  Nevins et al. reported that an 
uncontrolled diabetic state resulted in qualitative alterations, as evidenced by the presence of an 
immature and less organized newly formed bone following placement of titanium implants in the 
rat femur. However, the quantity of bone formation was similar for the diabetic and control 
groups.25 Giglio et al. demonstrated delayed peri-implant bone formation and the presence of a 
less mature bone in an experimental diabetes model. Two weeks after implant placement, the 
peri-implant bone in the diabetes-induced group was comprised of woven bone as compared the 
bone surrounding the implants in the non-diabetic controls that was comprised of lamellar 
bone.74 Siqueira et al. also demonstrated delayed peri-implant bone formation at a later stage, 30 
days after implant placement, the control group showed higher lamellar bone deposition around 
the implants, whereas only a think layer of lamellar bone was present in the diabetic group. 
Transmission electron microscopy revealed chondrocyte-like cells surrounded by a cartilaginous-
like matrix in the peri-implant area in the diabetic group.75 A later study confirmed the 
aforementioned qualitative differences between diabetic and non-diabetic rats, it was reported 
that the control group presented well-defined bone formations whereas no such formations were 
observed in the diabetic group.76 Furthermore, histomorphometric analysis has demonstrated 
differences in osseous healing between diabetic and non-diabetic animals. Takeshita et al. 
reported that bone formation was affected in an uncontrolled diabetes model, hydroaxyapatite 
implants presented with reduced bone contact, bone contact thickness and bone contact area.77 
However, in a later study of the same experimental group, bone thickness was lower only 84 
days, but not 28 or 56 days after titanium implant placement, demonstrating that the type of 
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implants may have an effect on bone thickness.78 Bone-to-implant contact has been reported to 
be statistically significantly lower in diabetic than non-diabetic rats.25,74-79 Nevins et al reported 
that the statistical significance of the difference between the diabetic and non-diabetic groups 
shown 4 weeks after implant placement, was not longer evident at a later stage of the healing 
process of 8 weeks.25 Ottoni and Choppard confirmed that bone-to-implant contact is statistically 
significant lower in diabetic rats than non-diabetic rats, it was reported that little osteogenic 
activity occurred during the second and third weeks, and the period of highest osteogenic activity 
was at the beginning of the fourth week and at the end of the fifth week.76 In a later stage of the 
osseous healing process (12 weeks after implant placement), two animal studies reported that the 
bone-to-implant contact figures in the diabetic group were comparable to the control group 80,81 A 
study conducted by McCracken et al. performed biochemical analysis at 2 weeks; diabetic 
animals demonstrated increased serum osteocalcin levels as compared to non-diabetic controls, 
whereas alkaline phosphatase levels were statistically significantly reduced.79 Overall, 
experimental studies have suggested that diabetes may be associated with a delayed osseous 
healing response around implants as evidenced by qualitative and quantitative differences.11, 21, 23, 
25, 73-80 However, no infectious complications or implant loss were associated to diabetes in 
animal models, suggesting that osseointegration con be accomplished even though they 
presented with impaired bone healing.25,80 Finally, some studies have examined the effect of 
insulin therapy on bone healing after implant placement based on the premise that diabetic 
animals treated with insulin demonstrate osteoid formation and bone growth at rates similar to 
controls.82,85 Fiorellini et al. demonstrated that strict insulin therapy was able to upregulate the 
formation of bone around implants inserted in the streptozotocin-induced diabetic rat model. 
However, there was significantly less bone-to-implant contact in the insulin-controlled diabetic 
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group as compared with non-diabetic controls.86 Siqueira et al. reported that bone growth area 
and bone-to-implant contact were not statistically different between the insulin-treated and 
control groups.75 These studies have demonstrated that the use of insulin around implants may 
reduce the deleterious effects of diabetes on osseous healing.72 
The experimental studies on osseous healing around implants in diabetic animals 
mentioned before were conducted in proven models for T1DM; even though they represent a 
hyperglycemic state, they do not represent the most prevalent diabetes type for which dental 
therapy in humans is considered. Therefore, the effect of T2DM on implant osseointegration, has 
not been addressed in an appropriate animal model.21 The first investigation assessing the effect 
of T2DM on the osseointegration capacity around titanium implants placed on a T2DM rat 
model was conducted by Hasegawa et al. Otsuka Long-Evans Tukoshima Fatty rats were 
genetically modified to become a T2DM model symptomatically analogous to human T2DM.87-
90 Titanium implants with a chamber were implanted into rat femorae. Histologic and 
histomorphometric analysis showed that the peri-implant cortical bone volume was consistently 
smaller in the diabetic animals as compared to the control animals in a period of 4 to 8 weeks, 
while the bone volume in the marrow area was not affected by the diabetic condition. In terms of 
bone-to-implant contact percentage, it was considerably low for the diabetic group in the cortical 
and marrow areas, being 12% for the diabetic group and 61% for the control group at 4 weeks; a 
2-fold difference was still present at week 8. The poor bone-to-implant contact observed in 
diabetic rats was associated with the presence of fragmented bone tissues and extensive soft 
tissue intervention.21 Wang et al. conducted an experimental study on Goto-Kazizaki (GK) rats, 
which are a genetic animal model of T2DM produced by selective breeding of an outbred colony 
of Wistar rats, with selection for high glucose levels in an oral glucose tolerance test.91 This 
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study investigated the effects of T2DM on implant osseointegration at 4 and 8 weeks after 
implantation in the femora. At 4 weeks, it was observed that woven bone and fibrous tissue 
surrounded the implants in the diabetic group, in contrast the control group presented lamellar 
bone surrounding the implant. At 8 weeks, differences between the control and the diabetic 
group were still present. The peri-implant area of the diabetic animals presented large amount of 
fibrous granulation tissue and extensive bone resorption, whereas the peri-implant are of the 
control animals presented with well organized and dense lamellar bone. Also, the control group 
demonstrated an extensive area of bone-to-implant contact, while in the experimental group there 
was a mixture of bone and soft tissue at the implant interface. The percentage of bone-to-implant 
contact and trabecular bone volume increased over time in the diabetic group, however they did 
not reach the control percentages, except for trabecular bone volume at 4 weeks.92 Another 
experimental study conducted by Colombo et al. examined the expression of specific cellular 
markers involved in osseous healing around titanium implants placed in the incisor socket of GK 
rats. Histology demonstrated a delay in the bone mineralization around implants placed in 
diabetic rats. Immunohistochemistry suggested that the plausible mechanism for this delay in 
bone healing is a result of a prolongation in cellular proliferation and in the synthesis of 
osteoprotegerin (OPN) with subsequent effects in delaying the synthesis of osteocalcin (OCN). A 
significant finding in this study was a delay in the expression of TGF-β1	  in the diabetic group, 
which was apparent at week 3 and high levels were maintained upto week 9. This delayed 
expression may be an important change in the signaling milieu due to a prolongation of the cell 
proliferation, delayed osteoblast differentiation and therefore osseous formation.  Also, this study 
found elevated levels of proinflammatory cytokines (IL-1β and TNF-α) and macrophage 
numbers in the diabetic bone. The authors speculated that the raised levels of pro-inflammtaroy 
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cytokines act on mesenchymal progenitors by stimulating cell proliferation and inhibiting 
differentiation. This study proposed that changes in the signaling milieu, might affect the 
proliferation and differentiation of mesenchymal progenitor cells during the osseointegration 
phase.93 
Pertaining to clinical studies; it has been concluded from retrospective13,14,16 and 
prospective studies12,15,17,19  that high survival rates may be obtained in patients with diabetes, 
given that patients present an adequate glycemic control. A retrospective study by Fiorellini et al. 
showed that implant survival rate was lower in well-controlled diabetic patients as compared to 
non-diabetic individuals; however there was still a reasonable success rate.94 Oates reported that 
there are no clear clinical data supporting increased implant failures for patients lacking good 
glycemic control and, in fact, more recent studies support the used of dental implant therapy for 
patients in the absence of good glycemic control with appropriate accommodations for delays in 
implant integration.4  
 Decreased levels of implant osseointegration and alterations in the bone metabolism 
have been demonstrated in hyperglycemic animal models. The extrapolation of these concerns to 
dental implant therapy, while indirect, certainly supports caution.4 Clinical studies are 
contradictory to the experimental studies; numerous investigations have shown that implants 
could be placed with high survival rates in diabetic patients.95 Some of these clinical studies 
reported some early failures of implants before osseointegration could be established.13-17 
Fiorellini et al. did not observe any early failures, the author speculated that since most of the 
failures in his study occurred during the first year, this could have been attributed to a 
mechanical overload, caused by a diabetes-induced lower percentage bone-to-implant contact, 
immature, or incorrectly formed bone.94 Similar to this finding, Shernoff reported that the failure 
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rate increased after one year of loading.17 Other than failure rates and implant survival, outcomes 
of dental implants placed in patients with diabetes have not been studied extensively. According 
to a meta-analysis by Chrcanovic et al, concerning maginal bone loss, there was a statistically 
significant difference between diabetic and non-diabetic patients, favoring non-diabetic 
patients.94 In regard to post-operative infections, few studies have provided information, and 
therefore a meta-analysis was not possible. 94 
The clinical applicability and predictability of dental implants in the healthy patients has 
been studied and confirmed extensively. Long-term success has been shown utilizing endosseous 
implants and their predictability relies on successful osseointegration formed during the healing 
period.6 While experimental models have provided evidence that DM affects the process of 
ossointegration, the applicability to dental implants placed in human subjects requires caution. 
Furthermore, the bone formation disturbance reported systemically and locally to the 
periodontium cannot be assumed to apply to endosseous implants.6   Succesful treatment of 
patients with diabetes is well documented. However, the impact of DM on osseous healing 
around dental implants placed on human subjects is unclear. To the best of our knowledge, there 
are no controlled human studies examining the effects of DM on the implant-bone interphase and 
early phases of osseointegration. Insufficient information is available to determine how DM 
affects the process of osseointegration in human subjects.  It will be important to examine the 
molecular pathways that may affect osseointegration,6 in both health and disease. 
According to the literature and within the limits of the available investigations, we 
hypothesize that during the initial phase of wound healing and osseointegration of 
endosseous dental implants, patients with T2DM will present with delayed osseous healing 
in comparison to healthy subjects.  
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  One of the scientific merits of this study is to understand early osseous healing around 
dental implants at a molecular level in terms of gene expression in human subjects. Furthermore, 
this study could help understand differences in osseous healing in diabetic patients as compared 
to healthy individuals. Unraveling the pathways of osseointegration around dental implants will 
lead to improved treatment strategies to optimize the outcomes, specially in a population that 
represent the most prevalent diabetes type for which dental therapy is considered. In addition, 
understanding the systemic conditions that place the patient at a higher risk of implant 
complications and failure will allow the clinician to make informed decisions and improve the 
treatment modalities.95  
Statements of purpose, hypothesis and specific Aims: 
The process of early osseous healing around dental implants in patients with T2DM has not been 
explored. Previous experimental and clinical studies have shown that DM could affect the stages 
osseous healing. However, due the heterogeneity of clinical studies and the inability to 
extrapolate findings from experimental studies, there is not sufficient and conclusive information 
to understand osseous healing. We are seeking to understand the gene expression and molecular 
pathways that modulate osseous healing since they are crucial for implant osseointegration and 
treatment outcomes, and could possible explain the delayed osseous healing observed in patients 
with diabetes as well as the early or late failures that have been reported in the literature. Two 
specific aims are developed to test our hypothesis that during the initial phase of wound 
healing and osseointegration of endosseous dental implants, patients with T2DM will 
present with delayed osseous healing in comparison to healthy subjects. 
Aim 1: to identify differentially expressed genes and those molecular pathways that 
modulate osseous healing around dental implants.  
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 In this aim, we will first identify differentially expressed genes and those molecular 
pathways that modulate osseous healing at two and four weeks after implant placement by 
placing titanium test cylinders that permit vascular and osseous ingrowth in patients with 
diabetes and healthy subjects. A biological sample obtained from each test cylinder will be 
processed for RNA extraction and gene expression profiling using Affymetrix (Affymetrix Inc., 
Santa Clara, CA) recommended procedure and analyzed using Partek and IPA software. Gene 
expression data seen on the Affymetrix array will be confirmed by PCR array method 
(SABioscences) for human osteogenesis panel. Patterns in gene expression will help to have an 
insight into the dynamics of osseous healing response around dental implants. 
Aim 2: to compare the differences in the gene expression at two and four weeks after 
implant placement in patients with T2DM and healthy individuals.  
After identifying the differentially expressed genes and molecular pathways that modulate 
osseous healing, we will examine the differences in gene expression profiles comparing patients 
with T2DM and healthy subjects. This will allow understanding a plausible mechanism for the 
impaired and delayed wound healing that has been previously reported.  
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CHAPTER 2: OSTEOGENIC ACTIVITY ASSOCIATED WITH DENTAL 
IMPLANT PLACEMENT IN PATIENTS WITH TYPE 2 DIABETES 
MELLITUS AS COMPARED TO HEALTHY INDIVIDUALS 
 
Introduction 
 
Diabetes mellitus (DM) is a chronic metabolic disorder characterized by hyperglycemia 
due to impaired insulin secretion, insufficient action or both.1 Type 2 diabetes mellitus (T2DM) 
is characterized by impaired insulin function and accounts for 90 to 95% of patients with 
diabetes.2 In the aging population, in which both tooth loss and DM coexist, the need for oral 
rehabilitation with dental implants is high.3 The use of dental implants in patients with DM is a 
debatable issue due to the adverse effects of hyperglycemia on osseointegration.4 The 
predictability of implant therapy relies on the osseointegration formed during the healing period,5 
and the critical dependence on bone metabolism for implant survival may be heightened in 
patients with DM.3   
The underlying pathophysiology responsible for impaired wound healing and 
osseointegration has been related to several mechanisms. Hyperglycemia increases the formation 
of advanced glycation end products (AGEs), which cause qualitative and quantitative changes in 
extracellular matrix (ECM) components.6 These changes affect cell adhesion, growth and matrix 
accumulation.5 AGEs interact with receptors for AGEs (RAGEs) present on endothelial cells, 
smooth muscle cell, neurons, and monocytes/ macrophages.7 The wound healing capacity is 
impaired since endothelial cell basement membranes build up AGE modified collagen causing an 
increased thickness in the microvasculature leading to an altered normal homeostatic transport 
across the membrane,8 impaired migration of leukocytes, decreased oxygen diffusion, and 
Fig.1 
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elimination of metabolic waste.9,10 The interaction of AGEs with RAGEs present in monocytes 
causes an increase in cellular oxidant stress and activation of NF-kB, which alters the 
monocyte/macrophage phenotype resulting in an increase of pro-inflammatory cytokines (IL-1β, 
TNF-α,7,8 IL-611), MMPs and adhesion molecules.12 An overproduction of these products can 
amplify the inflammatory response, delaying wound healing and inducing bone resorption and 
connective tissue damage.13 Furthermore, increased levels of AGEs in bone collagen may affect 
cellular, structural, and functional characteristics leading to alterations in bone metabolism.14-16  
The effect of DM on osseous healing has been extensively studied; models of 
experimentally induced diabetes have shown decreased cellularity and impaired osteoid matrix 
formation during the early phases of osseous healing possible due to a defficit in the recruitment 
of mesenchymal stem cells (MSCs) in the osteoblastic lineage, impaired differentiation and 
proliferation, and suppresed osteoblastic activity.17,18 Decreased expression of transcription 
factors necessary for the acquisition of the osteoblastic phenotype has been observed in the early 
phase of intramembranous ossification suggesting a possible mechanism for the impaired 
commitment of MSCs in the osteoblastic lineage.19 Plausible mechanism responsible for the 
reduction in cell proliferation is that DM may downregulate pathways involved in cell division, 
energy production and osteogenesis during the proliferative phase of intramembranous bone 
healing.20 Also, DM may decrease the levels of growth factors involved in early osteogenesis by 
altering the normal progression of the inflammatory phase and osseous formation. 21, 22  
Experimental studies have suggested that diabetes may be associated with a delayed 
osseous healing response around implants as evidenced by qualitative and quatitative 
differences.23-30 These studies have reported that diabetic animals presented with impaired new 
bone formation,23,24 immature and less organized newly formed bone25,26, delayed peri-implant 
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bone formation,27 reduced bone-to-implant contact25-30, and decreased alkaline phosphatase 
levels.30 However, no infectious complications or implant loss were associated to diabetes in 
animal models, suggesting that osseointegration can be accomplished even though they presented 
with impaired bone healing.25,31 Most of the experimental studies on diabetes have been 
conducted in proven models for T1DM; even though they represent a hyperglycemic state, they 
do not represent the most prevalent diabetes type for which implant therapy in humans is 
considered. Later investigations have studied the effect of diabetes on implant osseointegration 
in experimental T2DM models,32-34 and reported smaller volume of peri-implant cortical bone,32 
decreased bone-to-implant contact,32,33 decreased maturation,33 delayed bone mineralization and 
expression of TGF-B1,34 and elevated levels of pro-inflammatory cytokines.34 
In regard to clinical studies; it has been concluded from retrospective35-37 and prospective 
studies38-41 that high survival rates may be obtained in patients with DM. Some clinical studies 
reported some early implant failures before osseointegration could be established.35-40 However, 
other studies have reported later failures40,42 that could be attributed to a mechanical overload, 
caused by a diabetes-induced lower percetage bone-to implant contact, immature, or incorrectly 
formed bone.42 
Succesful implant placement in patients with diabetes has been confirmed. However, the 
impact of DM on osseous healing around implants placed on human subjects is unclear. While 
experimental models have provided evidence that DM affects the process of implant 
osseointegration, the applicability to dental implants placed in human subjects requires caution. 
Furthermore, the bone formation disturbance reported systemically and locally to the 
periodontium cannot be assumed to apply to endosseous implants.5  
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To the best of out knowledge, there are no human studies examining the effects of DM on 
the implant implant-bone interphase at the early stages of osseointegration in terms of gene 
expression and pathway analysis. Furthermore it is important to examine the molecular pathways 
that modulate implant osseointegration5 in both health and disease to understand and explain the 
delayed osseous healing observed in patients with diabetes as well as the early or late failures 
that have been reported in the literature.  
In this study we are aiming to identify differentially expressed genes and those molecular 
pathways that modulate osseous healing around dental implants in bone biopsies obtained from 
healthy individuals and patients with T2DM at two and four weeks after implant placement.  We 
are also seeking to compare the differences between patients with T2DM and healthy individuals 
to test our hypothesis that during the initial phase of wound healing and osseointegration of 
endosseous dental implants, patients with T2DM will present with delayed osseous healing as 
compared to healthy subjects.  
Materials and Methods 
Participants and bone biopsy collection 
 
This study was approved by the Biomedical Institutional Review Board of the University 
of North Carolina at Chapel Hill (UNC). Written informed consent was obtained from all study 
participants. The study population consisted of 10 adults in adequate periodontal health that were 
elegible and treament planned to receive mandibular dental implants. The control group 
consisted of 4 systemically healthy individuals, and the experimental group consisted of 6 
patients with T2DM with HbA1c levels of 7.0-8.9. Major exclusion criteria included: use of 
medications known to affect periodontal staus within one month prior to initial examination, 
systemic conditions (except T2DM) that are known to affect periodontal status, history of IV 
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bisphosphonates, active infectious disease, pregnancy, current smokers or history of smoking 
within the last two years, subjects with blood disorders and/or anticoagulant therapy, 
chemotherapy, and radiotherapy. An edentulous ridge area with sufficient space to place two 
titanium test cylinders  (each approximately 2.9-3 x 5 mm) was confirmed radiographically, 
followed by a CBCT taken with a radiographic stent. For each patient, two titanium test 
cylinders were placed on the mandible at the level of the crestal bone and covered with a 
collagen membrane (BioMend, Zimmer Dental, Carlsbad, CA, USA) to prevent soft tissue 
downgrowth, primary closure was obtained. Test cylinders were removed at two and four weeks 
using a slightly larger trephine drill and sites received a screw vent implant (Zimmer Dental, 
Carlsbad, CA, USA). Each test cylinder was placed into microfuge tubes containing RNAlater 
solution and temporarily stored at 4ºC overnight. The next morning, the solution was decanted 
and the samples were flash frozen in liquid nitrogen and stored at -80ºC until analysis.  
RNA isolation and quality control 
Total RNA was isolated from the bone biopsies using a miRNAeasy Mini Kit (QIAgen, 
Valencia, CA, USA) according to the manufacturer's instructions. RNA quality and purity were 
analized by spectophotometer using the NanoDrop ND-1000 and Agilent 2100 Bioanalyzer.  
Gene expression analysis 
One microgram of RNA was reversed transcribed using Omniscript Reverse 
Transcriptase kit (QIAgen, Valencia, CA, USA) in a total volume of 20ul to obtain the first 
strand cDNA according to the manufacturer's instructions. Whole transcriptome gene expression 
profiling was performed using Affymetrix Human gene 1.0ST (Affymetrix Inc, Santa Clara, CA) 
and analyzed using Partek (Partek Inc., St Louis, MO, USA) and IPA (QIAgen, Valencia, CA, 
USA) software programs.  
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Quantitative Real-time PCR 
Gene expression data seen on the Affymatrix arrays was confirmed with quantitative real-
time PCR. RNA was reverse transcribed to cDNA using RT2 first strands kit (QIAgen, Valencia, 
CA, USA). To examine genes of interest, we used human osteogenesis RT2 Profiler PCR Array 
(PAHS-026Z) in a 7500 Sequence Detection system (ABI prism, Applied Biosystems). The 
human osteogenesis panel included the following functional gene groups: skeletal development, 
bone mineral metabolism, cell growth and differentiation, extracellular matrix molecules and 
transcription factors and regulators.  
Statistics 
 Since it was not feasible to obtain bone biopsies representative of baseline gene 
expression levels (at implant placement), we used gene expression data observed in healthy 
subjects at 2 weeks post-cylinder placement as our reference point. First we compared gene 
expression at 4 weeks to 2 weeks in healthy individuals and second, we compared gene 
expression changes at 4 weeks in patients with T2DM to healthy individuals at 2 weeks. We also 
analyzed gene expression in patients with T2DM as compared to healthy individuals at 2 and 4 
weeks. SAM analysis using an FDR of P<0.05 was used to determine significant differences in 
gene expression and molecular pathways between patients with T2DM and healthy individuals. 
We also reported p-values obtained from ANOVA test to compare differences in expression of 
the top molecules observed and specific genes associated with human osteogenesis (P<0.05). 
Gene expression data seen on the Affymetrix arrays was confirmed by quantitative PCR array 
analysis. The mRNA expression levels were normalized using multiple housekeeping genes and 
the fold changes were calculated by means of 2-∆∆CT method, using a web-based RT2 profiler 
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PCR array data analysis version 3.5. We also used the Chi square test for proportions to 
determine whether T2DM influenced gene expression of genes involved in human osteogenesis.  
Results 
Demographic information of the study participants 
 The demographic information, including age, gender and race are listed in Table 1. The 
mean age of the study participants was 63.7+5.8 years. There was an even sex distribution and 
the study group consisted of  7 Caucasians and 3 African Americans.  
Expression of top molecules obtained from Affymetrix analysis 
Table 2 shows the p-value from ANOVA, FDR p-value and fold change of the top 
molecules expressed when we compared healthy individuals at 4 weeks versus 2 weeks, and 
patients with T2DM at 4 weeks to healthy individuals at 2 weeks. We observed that DSG3, 
S100A7, KRT13, TMPRSS11A, SPR1A, and GPB6 appeared significantly upregulated at 4 
weeks as compared to 2 weeks in healthy patients (p<0.05). When we compared these same 
molecules upregulated at 4 weeks in healthy patients to 4 weeks in patients with T2DM we 
observed that they appeared downregulated in the diabetic group. SPPR1B was significantly 
expressed at 4 weeks in healthy patients and was not expressed at 4 weeks in patients with 
T2DM (p<0.05). Healthy patients presented downregulation of OGN, WDR72, SEMA3D, DPT 
and CHAD at 4 weeks (p<0.05), whereas patients with T2DM presented upregulation of these 
molecules. Patients with T2DM presented upregulation of DNASE1L3, MYRIP and SOST at 4 
weeks (p<0.05), whereas healthy patients presented with downregulation of these molecules. 
SERPINB3, DSG1, SPPR3 were upregulated at 4 weeks in both healthy and diabetic groups, 
however the upregulation was only statistically significant in the healthy group (p<0.05) and they 
also presented with a higher fold change expression. BEND6, DPT, and IFITM5 were 
  
 
29 
downregulated at 4 weeks in both healthy and diabetic groups; this downregulation was only 
statistically significant in the healthy group (p<0.05). None of these molecules had a FDR p-
value of <0.05. 
Expression of genes involved in human osteogenesis obtained from Affymetrix analysis 
 To obtain an insight of the gene expression and associated pathways involved in 
osteogenesis around dental implants, we analyzed specific genes associated with human 
osteogenesis and created a pathway using these genes. Also, we included the associated 
canonical pathways pertinent to healing around endosseous implants. Figure 1 shows the 
expression of genes associated with human osteogenesis and their interactions in healthy patients 
at 4 weeks as compared to 2 weeks, showing that the majority of the human osteogenesis genes 
appeared downregulated at this time point. VEGFB, SMAD3, COL3A1, FGFR1, CTSK, BGN, 
COL2A1, TGFBR2, COL5A1, COL1A2 and TGFB3 appeared significantly downregulated and 
only VEGFA appeared significantly upregulated (p<0.05, Table 3).  Figure 2 shows the gene 
expression of human osteogenesis genes in patients with T2DM at 4 weeks as compared to 
healthy patients at 2 weeks; we observed that some genes that appeared downregulated in the 
healthy group at 4 weeks appeared upregulated in the diabetic group. However, SPP1 and ITGB1 
appeared statistically significant downregulated (p<0.05, Table 4), and only SPP1 had a FDR p-
value of <0.05. Figure 3 shows the expression of human osteogenesis genes weeks comparing 
the diabetic group versus the healthy group at the same time point of 2 weeks. BMPR1B, 
TGFBR2, CALCR, ANXA5 and IGF1 appeared downregulated in the diabetic group as compared 
to the healthy group (p<0.05, Table 5). However, only BMPR1B had a FDR p-value of <0.05. 
Figure 4 shows the expression of human osteogenesis genes comparing the diabetic group versus 
the healthy group at 4 weeks. The majority of the genes appeared upregulated in the diabetic 
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group; CD36, MMP8, SP7, BMP4, DLX5, SOX9, RUNX2, COL1A2, BMPR1A, GLI1, COL1A1 
and TGBR appeared upregulated and ICAM1 was downregulated (p<0.05, Table 6), none of these 
genes had a FDR of p<0.05. To confirm if the osteogenesis pathway was significantly 
upregulated or downregulated in all our group comparisons, we created Chi square contingency 
tables for all the possible combinations. However, only in the diabetic group versus the healthy 
group at 4 weeks, the osteogenesis pathway was statistically significant upregulated when we 
compared to the healthy group 4 weeks versus two weeks (p<0.001, Table 7), diabetic group at 4 
weeks versus healthy group at 2 weeks (p=0.0016, Table 8), and diabetic versus healthy at 2 
weeks (p=0.0044, Table 9).  
Real time quantitative PCR 
 Using real time PCR we confirmed downregulation of COL1A2, COL2A1, CTSK and 
upregulation of VEGFA from 2 weeks to 4 weeks after implant placement in healthy individuals. 
Comparing patients with T2DM versus healthy individuals at 2 weeks, we confirmed that IGF-1 
was downregulated in patients with T2DM. We also confirmed that at 4 weeks, patients with 
T2DM showed upregulation of SP7, COL1A2, COL1A1, CD36, MMP8, BMP4, RUNX2, SOX9, 
DLX5, and downregulation of ICAM1 as compared to healthy individuals.  
Discussion 
The pattern of osseous healing around dental implants with different surfaces has been 
characterized in cell culture systems, animal studies, and human biopsies.43 However, the 
mechanisms underlying the process osseointegration have not been fully elucidated. 
Transcriptome studies have demonstrated that complex genetic networks are associated with 
implant osseointegration.43 Still, these complex associations requiere to be further studied to 
understand gene expression events and their effect on osseointegration in both health and disease. 
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To the best of our knowledge this is the first human study that has analyzed gene expression and 
molecular pathways after implant placement in healthy and diabetic patients using Affymetrix 
analysis, and also for a period of more than 2 weeks after implant placement.  
 In this study, we isolated RNA from bone biopsies obtained from healthy subjects and 
patients with T2DM at 2 and 4 weeks after titanium test cylinder placement to identify 
differentially expressed genes and those molecules that modulate osseous healing around dental 
implants in both health and T2DM. We also compared the differences in the expression of genes 
involved in human osteogenesis at two and four weeks after implant placement in patients with 
T2DM as compared to healthy individuals to find a plausible explanation of the delayed osseous 
healing and the early or late implant failure that has been reported in the literature.   
 Table 10 shows a summary of the top molecules obtained analyzing Affymetrix data 
using IPA software (QIAgen, Valencia, CA, USA) and the main biologic processes in which 
they are involved. Healthy patients presented with a significant increased fold change of DSG3, 
S100A, KRT13, TMPRSS11A, SPR1A, and GPB6 at 4 weeks as compared to 2 weeks. However, 
we observed that these molecules appeared downregulated in the diabetic group at 4 weeks as 
compared to 2 weeks in healthy individuals. It is interesting that SPPR1B had a fold change of 
165.8 in the healthy group from 2 to 4 weeks, but it was not expressed in the diabetic group. 
Healthy patients presented with downregulation of OGN, WDR72, SEMA3D, DPT and CHAD 
from week 2 to week 4, whereas this molecules appeared upregulated in the diabetic group at 4 
weeks. These findings suggest that the timeline of osseous healing around dental implants in 
diabetic patients is different from that of the healthy subjects at 2 and 4 weeks after implant 
placement. Furthermore, patients with T2DM presented an increased fold change of DNASE1L3, 
MYRIP and SOST at 4 weeks, whereas healthy patients presented downregulation. We 
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speculated that increased expression of DNASE1L3 and SOST in the diabetic group at 4 weeks 
could have a detrimental role in osseous healing. DNASE1L3 is associated with apoptosis and 
DNA catabolic process. SOST, which is predominantly expressed by osteocytes, is associated 
with negative regulation of BMP signaling pathway, negative regulation of canonical Wnt 
receptor singnaling pathway, and negative regulation of ossification and protein complex 
assembly.44 The Wnt signaling pathway has important biological roles in cell differentiation, 
embryogenesis, and tissue homeostasis,45 it has been recognized as an important regulator of 
osteoblast activity.46 Canonical Wnt/β-catenin signaling result in expression of the transcription 
factors Runx2 and SP7 (osterix), which in turn modify the pangenomic expression patterns of 
MSCs and lead to ordered osteogenic differentiation.43 When sclerostin binds to the low-density 
lipoprotein receptor-related proteins 5 and 6 (LRP 5/6) complex on the cell surface of osteoblasts, 
it prevents Wnt ligand attachment and thereby it inhibits Wnt signaling, resulting in inhibition of 
osteoblastic bone formation.47-50 Ivanovski et al. conducted the first whole transriptome study to 
determine the temporal gene expression profile associated with the early healing events during 
osseointegration in a human model at days 4, 7 and 14 following implant placement.51 They 
observed that the main signalling pathways that were associated with the increase in 
skeletogenesis-related gene expression after dental implant placement were TGF-β/BMP, Wnt 
and Notch. The Wnt pathway appeared to play an important role at the early phases of 
osseointegration around implants during all the study period of 14 days.51 Thefore, the 4-fold 
upregulation of SOST seen in patients with T2DM at 4 weeks as compared to healthy patients at 
2 weeks suggests that this group could present negative regulation of the Wnt signaling pathway 
and thus present with decreased osteoblastic activity and by consequence impaired osseous 
healing around dental implants.  
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Using IPA software (QIAgen, Valencia, CA, USA), we created a pathway that included 
genes involved in human osteogenesis to obtain an insight of the gene expression and changes at 
2 and 4 weeks in both health and T2DM. We were not able to find a statistically significant 
difference in gene expression in the majority of the human osteogenesis genes. However, we 
observed that in healthy individuals there was a fold change decrease of the majority of the genes 
at 4 weeks as compared to 2 weeks (Figure 1). In contrast patients with T2DM presented 
upregulation of key genes involved in increased osteogenesis at 4 weeks as compared to healthy 
patients at 2 weeks, including PHEX, RUNX2, DLX5, and SP7 (Figure 2). We also observed that 
when we compared gene expression at 4 weeks in patients with T2DM versus healthy individuals 
the majority of the genes involved in human osteogenesis appeared upregulated in the diabetic 
group (Figure 4) These findings suggest that patients with T2DM present with increased 
osteogenic activity at 4 weeks as compared to healthy subjects, however we speculate that this 
could reflect that the increased osteogenic activity observed after implant placement in healthy 
patients occurred before 4 weeks and at this time point they are already showing downregulation. 
The observations made from this clinical study suggest that patients with T2DM present with 
delayed osseous healing around dental implants as compared to healthy patients. 
Table 11 shows a summary of some the human osteogenesis genes analyzed and the main 
biologic processes in which they are involved. Employing real time PCR we confirmed data 
from Affymetrix and we observed that during the osseous healing around titanium implants there 
was downregulation of COL1A2, COL2A1, CTSK and upregulation of VEGFA from week 2 to 
week 4 in the healthy group. It has been reported that CTSK, which is involved in receptor 
activity, appears upregulated from day 4 to day 14 after implant placement in healthy 
individuals.51 We speculate that Cathepsin K, which is an enzyme predominantly expressed in 
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osteoclasts and involved in bone remodeling and resportion52 presents an upregulation from 4 
days to 2 weeks after implant placement,51 followed by a decreased expression at 4 weeks in 
healthy patients suggesting that the bone remodeling and resorption phase is decreased at 4 
weeks after implant placement.   
 We also confirmed that patients with T2DM presented downregulation of IGF-1 at 2 
weeks as compared to healthy individuals. Patients with diabetes present specific alterations in 
bone metabolism associated with insulin since it stimulates osteoblastic matrix synthesis and 
indirectly stimulates IGF-1 production by the liver.5  IGF-1 is involved in skeletal system 
development, blood coagulation, positive regulation of cell proliferation, bone mineralization 
involved in bone maturation and positive regulation of osteoblast differentiation.53, 54 IGF-1 
increases matrix synthesis increasing the number of osteoblasts present and upregulates the 
function of differentiated osteoblasts.5 Several studies conducted on diabetic animal models that 
have assessed fracture healing have reported decreased expression of IGF-1 at fracture sites.21,22 
The downregulation of IGF-1 seen in patients with T2DM suggest that these patients present an 
altered bone metabolism that could delay and impair osteogenesis around dental implants.  
 Furthermore, patients with T2DM presented upregulation of COL1A2, COL1A1, CD36, 
MMP8, BMP4, SP7, RUNX2, SOX9, DLX5, and downregulation of ICAM1 at 4 weeks after 
implant placement as compared to healthy individuals. Ivanovski et al. reported that in healthy 
patients BMP4, CD36, and the transcription factors DLX5, SOX9 and SP7 were upregulated 
from day 4 to day 14 after implant placement in healthy patients.51 In our study, the diabetic 
group presented increased expression of these genes associated with positive osteogenic activity 
as compared to healthy individuals at 4 weeks. Collagen 1 is the most abundant protein in bone 
secreted during the early stages of osteoblast differentiation and it is suggestive of greater 
  
 
35 
osteogenesis and increased bone formation.55,56 BMPs are multifunctional cytokines belonging to 
the TGF-β superfamily, it has been observed that BMP4 is a key factor involved in bone 
development and repair. 57 BMP4 appears during the stages of periosteal response and primary 
bone formation during the process of bone fracture healing. Also, BMP4 from the bone matrix 
stimulates the production of VEGF.57 During osseous formation and fracture healing, a cross-talk 
is established between osteoblasts and endothelial cells.58 Osteoblast derived VEGFs play an 
important role in osseous healing since they may act as paracrine factors, modulating endothelial 
and osteoclast functions and they also act as autocrine factors, modulating osteoblast 
differentiation.59 VEGFA, that appeared upregulated at 4 weeks as compared to 2 weeks in 
healthy, is produced by osteoblasts in response to BMPs, couples angiogenesis to bone 
formation.58  
In addition, patients with T2DM presented upregulation of the trancription factors Runx2, 
SP7, SOX9 and DLX5 as compared to healthy individuals at 4 weeks. Runx2 is an early 
osteogenic trancription factor and is the main regulator during initial phase of osteogenesis,60 it 
binds to target gene promoters to affect their expression during osteoblastic differentiation and 
bone formation.61 SP7 (osterix) is required downstream of Runx2, it is the second key 
transcriptional regulator of osteoinduction,56 and is associated with osteoblast differentiation.62 It 
is interesting that in vitro studies of implant surface topographies propose that the greater bone 
formation observed in vivo is due, in part to surface-dependent modulation of the osteoinductive 
transcription factors Runx2 and SP7.56 DLX5, which also appeared upregulated, induces 
maturation of osteoblasts and inhibits osteocyte formation.60 Even though these findings could 
suggest a greater osteogenic activity in diabetic patients as compared to healthy individual at 4 
weeks due to an increase expression of osteogenic transcription factors, BMP4 and collagen; we 
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speculate that this incresed osteogenic activity occurred before 4 weeks in healthy patients and 
this accounts for the difference observed at 4 weeks.  
In addition a decreased expression of BMPR1B observed at 2 weeks in patients with 
T2DM, indicates a possible alteration in bone healing since BMPs exert their biologic effects by 
binding to this receptor, and the BMP signaling pathway induces osteoblastic differentiation 
through BMPR1B.63 Also, The decreased expression of SPP1 observed in the diabetic group at 4 
weeks suggests a possible decrease in bone remodeling and osseous repair. SPP1 has been 
defined as one of the major noncollagenous bone matrix proteins produced by osteoblasts.64 It 
appears to form an integral part of the mineralized matrix and is important to cell-matrix 
interaction. This protein is important in bone remodeling65 as well as fracture repair.66 Even 
though it is involved with bone resorption; it has a role in osteoblast differentiation and 
biomineral tissue development.64  
 This study has several limitations. First the samples size is limited. Also, we did not 
obtain a bone biopsy at baseline (at time of titanium cylinder placement) to be able to compare 
gene expression and molecules associated with osteogenesis from baseline to 2 and 4 weeks. 
Therefore we used the healthy group at 2 weeks as our reference. Ivanovski et al reported that the 
gene ontology categories of skeletal system development, bone development and ossification 
were predomintant at day 14 and that the majority of changes occurred between days 4 and 14. 
They described that this period was characterized by a transcriptional profile consistent with a 
maturing osteogenic wound, and that changes during this period could be considered to be 
characteristic of key events occuring during implant osseointegration.51 Our study did not 
include differences in gene expression before 2 weeks, therefore our analysis was limited to later 
stages of osseous healing that migh present with less osteogenic activity as compared to the 
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period of 7 to 14 weeks. However, by studying gene expression in a patient population that 
presents with delayed wound healing such as T2DM for an extended period of 4 weeks, we 
found differences in gene expression as compared to healthy individuals.  
Conclusion 
 Aside from obtaining an insight in gene expression and some molecular mechanisms 
associated with osseous healing around dental implants in health and T2DM, we concluded that 
patients with T2DM present important differences in gene expression and molecular pathways at 
2 and 4 weeks after dental implant placement as compared to healthy individuals. Our results 
indicate that patients with T2DM present with delayed osseous healing around dental implants as 
compared to healthy individuals since we observed an increased expression of early transcription 
factors for osteogenesis, BMP4, and collagen 1 at a later stage as compared to healthy 
individuals. Furthermore, an increase in the expression of SOST, which is involved in negative 
regulation of important pathways of osteoblastic activity, and a decreased expression of IGF-1 
leading to altered bone metabolism, suggest that osseous healing around implants is impaired in 
patients with T2DM. Also, a decreased expression of SPP1 and BMPR1B indicate possible 
alterations in the process of osseous healing. The clinical implications of this study is that better 
understanding of the osseointegration process could lead to improved treatment strategies aimed 
at enhancing osseointegration and long term success of dental implants in healthy individuals 
and patients with T2DM. Also, since patients with T2DM present with delayed wound healing, 
dental implant therapy timing might require to be adjusted in this group of patients to improve 
treatment outcomes and implant survival.  
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Table 1. Demographic information of the study participants 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Expression of top molecules in healthy individuals at 4 weeks as compared to 2 
weeks and patients with T2DM at 4 weeks as compared to healthy individuals at 2 weeks 
 
*ANOVA 
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Table 3. Gene expression of human osteogenesis genes at 4 weeks as compared to 2 weeks 
in healthy individuals 
 
*ANOVA 
 
 
 
 
 
 
 
 
Table 4. Gene expression of human osteogenesis genes comparing patients with T2DM at 4 
weeks versus healthy individuals at 2 weeks  
 
*ANOVA 
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Table 5. Gene expression of human osteogenesis genes comparing patients with T2DM 
versus healthy individuals at 2 weeks  
 
 
*ANOVA 
 
 
 
 
 
 
 
 
 
 
Table 6. Gene expression of human osteogenesis genes comparing patients with T2DM 
versus healthy individuals at 4 weeks. 
 
 
*ANOVA 
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Table 7.  Contingency table: patients with T2DM versus healthy individuals at 4 weeks as 
compared to healthy individuals at 4 weeks versus 2 weeks. 
 
 
*Chi square test p<0.001, Yates correction p<0.001 
 
 
 
 
 
 
 
Table 8. Contingency table: patients with T2DM versus healthy individuals at 4 weeks as 
compared to patients with T2DM at 4 weeks versus healthy individuals at 2 weeks 
 
 
*Chi square test p=0.0016, Yates correction p=0.0017 
 
 
 
 
 
 
 
Table 9. Contingency table: patients with T2DM versus healthy individuals at 4 weeks as 
compared to patients with T2DM versus healthy individuals at 2 weeks. 
 
 
*Chi square test p=0.0044, Yates correction p=0.0047 
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Table 10. List of genes and corresponding Gene Ontology classification 
 
 
 
 
 
Table 11. List of genes associated with human osteogenesis and corresponding Gene 
Ontology classification. 
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Figure 1. Human osteogenesis genes and associated canonical pathways (gene expression at 
4 weeks as compared to 2 weeks  in healthy individuals). 
 
 
Figure 2. Human osteogenesis genes and associated canonical pathways (gene expression at 
4 weeks in patients with T2DM as compared to healthy individuals at 2 weeks). 
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Figure 3. Human osteogenesis genes and associated canonical pathways (gene expression in 
patients with T2DM as compared to healthy individuals at 2 weeks). 
 
 
Figure 4. Human osteogenesis genes and associated canonical pathways (gene expression in 
patients with T2DM as compared to healthy individuals at 4 weeks). 
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